NCT04693520View on ClinicalTrials.gov

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2024

Conditions
Early Alzheimer's Disease
Interventions
DRUG

ALZ-801

ALZ-801 265 mg twice daily (BID)

Trial Locations (6)

Unknown

St. Anne's University Hospital, Brno

Motol University Hospital, Prague

Vestra Clinics, Rychnov nad Kněžnou

Brain Research Center, 's-Hertogenbosch

Brain Research Center, Amsterdam

Brain Research Center, Zwolle

Sponsors

Lead Sponsor

Alzheon Inc.
All Listed Sponsors
lead

Alzheon Inc.

INDUSTRY